Moderna — co-developer (with Merck) of mRNA-4157/V940, the most advanced personalized mRNA neoantigen vaccine in the clinic.
Late last week, the drug makers Merck and Cambridge-based Moderna announced that patients who received their melanoma vaccine after surgery were 42 percent less likely to have a recurrence or die within two years than those who did not receive the treatment. And, earlier this mon…
On October 26, 2026, Moderna Inc (NASDAQ: MRNA) CEO Stephane Bancel expressed optimism about the company’s personalized cancer vaccine, intismeran autogene, following phase 3 melanoma trial results that fell short of investor expectations. Bancel emphasized the vaccine’s potentia…
Test your knowledge with our new weekday mini crossword Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and aut…
Leaked confidential data. A major stock sell-off. Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results …
by EMMA KOPPELMAN | The National News Desk (TNND) — A personalized cancer vaccine reduced the risk of melanoma returning or patients dying by 42% when given with a standard immunotherapy drug, according to late-stage trial results released Thursday by drugmakers Moderna and Merck…
The vaccine was custom-brewed for each patient to match their tumor. A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. The vac…
Merck and Moderna report that the personalized mRNA plus mAb cancer therapy cleared its first phase 3 hurdle, cutting recurrence risk beyond pembrolizumab alone. Merck and Moderna announced positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autoge…
Moderna shares dropped as much as 25% on Thursday following the leak of partial data on its closely watched cancer vaccine developed with Merck. Shares of both drugmakers fell even though the data, released in full later Thursday following the leak, appeared meaningful for patien…
WASHINGTON (AP) — A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients' tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck. The vaccine was custom-brewed for each patient to match th…
Data for Merck and Moderna’s highly anticipated personalized cancer vaccine leaked online Thursday morning, days ahead of a headlining reveal at the European Society of Medical Oncology meeting in Spain. The results left analysts disappointed—and hoping that the real presentation…
On October 22 US Eastern Time, Moderna’s stock plunged 20.14% despite its Phase III trial for the personalized cancer vaccine Intismeran autogene meeting primary efficacy endpoints. The drop reflected a "sell the news" reaction following a sharp prior run-up and investor scrutiny…
SA Spotlight uses AI to summarize content published on Seeking Alpha. All summaries are reviewed by human editors prior to publication. Moderna (MRNA) shares tumbled about 17% on Thursday after leaked clinical data from the company's personalized cancer vaccine program triggered …
ESMO 2026 opens in Madrid with Merck and Moderna's mRNA-based personalized cancer vaccine intismeran autogene plus Keytruda as the most anticipated presentation; in August the partners reported the combination extended survival without disease recurrence. BioSpace also flags Summit Therapeutics/Akeso's PD-1xVEGF bispecific and antibody-drug conjugate data as headliners. Stifel's Dara Azar frames the investor question directly: after a cancer vaccine win, where is the next opportunity - a sign that this dataset could reset expectations across the personalized vaccine category.
Moderna was added to the Nasdaq-100 following positive Phase 3 data for its personalized cancer vaccine developed with Merck, which a Yahoo Finance analysis frames as a pivot toward oncology beyond a COVID-focused product set. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise spanning cancer and other conditions, with the investment thesis resting on whether the platform can extend across respiratory vaccines, oncology, and rare disease. For the neoantigen field, a late-stage win from a top-tier mRNA player validates personalized cancer vaccines as a commercial category, with the piece flagging progress of newer programs as the near-term swing factor.
Five-year data for intismeran autogene (mRNA-4157/V940) combined with pembrolizumab were presented at the ASCO Annual Meeting in Chicago from the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial, which enrolled 107 patients following melanoma surgery to test whether the combination prevented recurrence better than pembrolizumab alone. The individualized neoantigen therapy is built from each patient's own tumor using mRNA that instructs cells to make tumor proteins, teaching the immune system to distinguish cancer cells from normal ones. Long-term follow-up in the adjuvant melanoma setting is the durability signal underpinning the program's late-stage and commercial case.
Merck CEO Rob Davis told CNBC he expects the personalized cancer vaccine being developed with Moderna to become faster to manufacture over time, though the near-term focus is making sure supply and the market are ready for launch. The current turnaround spans roughly six weeks from sequencing a patient's tumor to hospital delivery, a cycle driven by the vaccine's design targeting each patient's specific tumor mutations rather than a one-size-fits-all approach, paired with Keytruda. Manufacturing cycle time is a direct lever on how many patients the partnership can reach and on the economics of the program.
Moderna fell 10% to $214.03 in morning trading as profit taking hit a steep run tied to its personalized cancer vaccine, while BioNTech slipped 2% to $88.59 and Pfizer edged up 0.3% to $29.54; the iShares Biotechnology ETF fell 2% against a roughly flat S&P 500. The pullback follows August news that intismeran autogene plus Keytruda met its primary endpoint in a late-stage melanoma trial, which had driven Moderna's best single-day gain. With a critical trial readout due later this month, the move underscores how concentrated the vaccine thesis has become in near-term catalysts.
Tempus AI (Nasdaq: TEM) announced an expanded, multi-year collaboration with Moderna (Nasdaq: MRNA) and Merck (NYSE: MRK) to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an investigational personalized cancer vaccine being developed in combinat…
Eric Lefkofsky, Founder and CEO of Tempus, shared Tempus AI’s post on LinkedIn, adding: “Sequencing is no longer just about matching a patient to an existing treatment – with individualized therapies, it’s becoming an integral part of the treatment itself. Tempus is at the forefr…
Personalized mRNA vaccines that train the immune system to hunt a patient’s own tumor mutations are nearing approval, but, as Pharma Voice’s Alexandra Pecci reports, building them may prove harder than discovering them. Merck and Moderna’s melanoma vaccine, intismeran autogene, r…
A syndicated patient-education piece walks through Merck and Moderna's individualized neoantigen therapy (INT) approach, using mRNA as the instruction-carrying molecule to train immune cells against each patient's tumor neoantigen fingerprint under a 'one medicine for one patient' framing. There is no new data here. The industry read is continued public-facing investment in the Merck-Moderna partnership narrative, keeping the program visible as it advances.
Summit organizers frame the field at an inflection point: Moderna and Merck have reported positive initial Phase 3 data for intismeran autogene in combination with Keytruda, putting the first regulatory approval of a personalized neoantigen cancer vaccine firmly within sight. The 3rd Annual Personalized Cancer Vaccine Summit (December 1-3, 2026) draws 80+ leaders from Moderna, Medici Therapeutics, Geneos Therapeutics, Nykode Therapeutics, Echo Immune, HDT Bio, Mayo Clinic, and Transgene. The stated agenda — development, manufacturing, delivery, and market access — is a useful proxy for where the industry sees its next bottlenecks now that proof-of-concept is largely settled.
Personalized neoantigen vaccines are moving from early proof to later-stage clinical validation. In melanoma, Moderna and Merck’s mRNA vaccine intismeran, combined with pembrolizumab, met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in a phase 3 trial. In head and neck cancer, Transgene’s personalized vaccine TG4050 induced durable immune responses in a phase 1 trial, but efficacy remains unconfirmed. The contrast matters for investors: melanoma has a positive efficacy signal, while head and neck still requires confirmatory data.
50% off your first year of any Quiver subscription Backtested trading strategies built on Quiver's datasets Be the first to see our newest insights and key updates across all datasets Track the top-performing stock portfolios held by U.S. politicians in Congress Find stocks with …
Moderna is leveraging the Phase 3 success of its personalized mRNA cancer vaccine to expand its pipeline into universal cancer vaccines and in-body immune cell modification technologies. A common-antigen targeted therapy requiring no patient-specific manufacturing process, along …
Merck & Co., Inc. (NYSE:MRK) shares rose as positive trial results for the personalized cancer vaccine intismeran autogene—developed with Moderna—revived investor interest, while MRK’s 13% stake in Personalis and support for Tempus AI’s $1.5B sale at $16.25 tie strategic sequenci…
The item highlights personalized mRNA cancer vaccines as a potential therapeutic direction, citing 2.1 million new U.S. cancer cases and 626,000 cancer deaths this year from the American Cancer Society. It identifies Moderna and Merck as a leading combination approach pairing an immunotherapy drug with an experimental made-to-order mRNA cancer vaccine, and says late-stage studies have shown success in directing the immune system toward tumor-specific mutations. The implication is that the field is moving toward late-stage, commercialized personalized vaccines, but the item also notes conflicting U.S. official signals about mRNA technology, safety, and potential.
Moderna and Merck reported that their personalized mRNA cancer vaccine mRNA-4157 met its primary endpoint in the Phase 3 INTerpath-001 trial, which enrolled 1,137 high-risk melanoma patients after complete surgical resection. The vaccine combined with Keytruda produced statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda monotherapy. The result added more than $50 billion in combined market value to the two companies, with Moderna’s stock rising 177% and adding about $44 billion, and is pushing oncology sequencing and diagnostics into the capital-markets spotlight. It also heightens speculation around Tempus AI’s Personalis bid and rivalry in the sequencing sector.
This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies recen…
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination …
Matteo S. Carlino, MD, PhD, FRACP, discussed V940 plus pembrolizumab data, safety, and administration in resected melanoma. CancerNetwork® spoke with Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institut…
MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-i…
By Julia Rock-Torcivia | August 31, 2026 A new investigational cancer vaccine developed by Merck & Co. and Moderna is customized based on the genome of each patient’s tumor, designed to teach their immune system to recognize the cancer as a foreign body. The companies are investi…
Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma. Matteo S. Carlino, MD, PhD, FRACP, a medical oncologist at Westmead and Blacktown Hospitals, a faculty member at Melanoma Institute Australia, and a c…
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma. The individualized vaccine, when paired with the existing immunotherapy, Keytruda, is the first and only combination …
Merck and Moderna just proved their cancer vaccine works, and the ripple effects reach far beyond either company. Five names stand to collect a toll on every single dose manufactured, but not all of them carry the same risk. Act now: the analyst who called NVIDIA in 2010 just nam…
Moderna and Merck say their personalized mRNA cancer vaccine significantly reduced the risk of melanoma returning or spreading. Get up-to-the-minute news sent straight to your device. Account processing issue - the email address may already exist Must be at least 8 characters, no…
Moderna’s Personalized Cancer Vaccine Scores Late-Stage Win Hickory Daily Record
Moderna’s Personalized Cancer Vaccine Scores Late-Stage Win Tulsa World
Test your knowledge with our new weekday mini crossword Matthew Herper covers medical innovation — both its promise and its perils. Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as…
On August 19, 2026, a single piece of clinical data sent Moderna's stock soaring 177% in one day—one of the largest single-day gains for an S&P 500 constituent in more than two decades. The personalized mRNA cancer vaccine intismeran autogene, co-developed by Moderna and Merck, m…
By The ASCO Post Staff Posted: 8/21/2026 10:29:00 AM Last Updated: 8/21/2026 9:47:23 AM Advertisement Merck and Moderna, Inc. have announced positive topline results from the phase III INTerpath-001 trial (ClinicalTrials.gov identifier NCT05933577) evaluating adjuvant treatment w…
What Is A Neoantigen Cancer Vaccine? The Science Behind Moderna-Merck's Melanoma Breakthrough NDTV Profit
Test your knowledge with our new weekday mini crossword Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we look at how a C…
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited. Interim data from a large trial showed the experimental vaccine, when combined with M…
Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which re…
A breakthrough cancer vaccine developed by Moderna and Merck is fueling hopes that the next revolution in medicine could be as transformative as the arrival of antibiotics, organ transplants or the first targeted cancer drugs. Moderna and Merck announced this week that their Phas…
Subscribe to Smithsonian magazine and get a FREE tote. A personalized cancer vaccine, used in combination with an existing treatment, helped prevent the return and spread of melanoma in a late-stage clinical trial, Moderna and Merck, the companies developing the drug, announced t…
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field A personalized mRNA cancer vaccine has delivered the first positive phase III readout for an individua…
Intismeran autogene, an individualized neoantigen therapy, makes history on Wall Street as well as within the industry following its first positive Phase III data in a form of melanoma Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not t…
Stéphane Bancel, Founding CEO at Moderna, shared an update from Moderna, on LinkedIn, adding: In 2020, mRNA helped change what was possible in infectious disease, as our teams worked to deliver a COVID-19 vaccine at unprecedented speed, in less than a year. Today, we announced th…
Test your knowledge with our new weekday mini crossword By Jason Mast, Matthew Herper, and Angus Chen Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Matthew Herper covers…
Merck and Moderna announced that their personalized mRNA vaccine regimen successfully passed a large Phase 3 trial, reducing the risk of melanoma return or spread. While the FDA has not yet approved the treatment, the companies note it is the first combination regimen to demonstrate success in potentially extending lifespans for high-risk resected melanoma patients.
Moderna and Merck announced that intismeran autogene plus Keytruda met its primary endpoints of improving RFS and DMFS in a Phase 3 study of 1,137 high-risk melanoma patients. The personalized vaccine is designed to teach the immune system to target tumor-specific mutations, offering a mechanism distinct from chemotherapy or broad immunostimulation.
Moderna and Merck announced positive late-stage trial results for a personalized mRNA therapy combined with Keytruda in melanoma patients who had their cancer surgically removed. The companies plan to share full data at upcoming medical meetings, noting that the treatment aims to increase the possibility of cure by intervening early in the disease course.
MSD and Moderna reported the first positive Phase III readout for an individualized neoantigen therapy (INT) combined with an mRNA-based cancer therapy. The data shows intismeran autogene plus pembrolizumab can facilitate longer cancer-free survival in completely resected stage IIB-IV melanoma compared to Keytruda alone.
Merck CEO Rob Davis highlighted the positive Phase 3 topline results for intismeran autogene plus Keytruda in the adjuvant setting for resected stage IIB-IV melanoma. He described the achievement as a defining moment for cancer research, validating the joint effort between Merck and Moderna scientists in developing this individualized neoantigen therapy.
Moderna and Merck announced that their experimental personalized vaccine, combined with Keytruda, kept melanoma from spreading or returning longer than Keytruda alone in a trial of 1,137 patients. Experts describe the approach as highly promising for delaying recurrence and extending survival, with implications potentially reaching beyond melanoma to other cancer types.
Moderna and Merck announced topline results for their Phase 3 personalized cancer vaccine trial, though full peer-reviewed data is pending. Medical oncologists describe the improvement in recurrence-free and metastasis-free survival as a true breakthrough, noting that success at this level for patient-specific mRNA vaccines addresses previous challenges in the field.
ABC News reports on the positive trial results for a personalized cancer vaccine in melanoma. The coverage underscores the significance of the Moderna and Merck partnership in delivering a treatment that targets specific tumor mutations to prevent disease recurrence.
Moderna President Stephen Hoge stated that if regulators approve the personalized cancer vaccine, thousands of patients with high-risk resected melanoma could benefit as soon as next year. The announcement comes as Moderna and Merck seek to establish this mRNA-based neoantigen therapy as a standard adjuvant treatment.
Following the announcement of successful Phase 3 trial results for the personalized cancer vaccine, Moderna's stock surged over 140% in a single week. Merck's shares also rose approximately 11%, reflecting investor optimism about the commercial potential and regulatory pathway for the intismeran autogene program.
MSD and Moderna reported positive Phase 3 results for intismeran autogene in combination with Keytruda, meeting primary endpoints for recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). The INTerpath-001 trial represents a historic win for the individualized neoantigen therapy class.
Moderna CEO Stéphane Bancel described the success of intismeran autogene as turning an aspirational vision into reality. The customized treatment uses patient tumor tissue to train the immune system, targeting high-risk melanoma stages that were surgically removed but carried a high chance of recurrence.
Moderna and Merck’s personalized mRNA vaccine met its main goal in a late-stage melanoma trial when combined with Keytruda. The treatment significantly reduced the risk of high-risk skin cancer returning compared to standard therapy, validating the neoantigen approach in a pivotal setting.
This week’s BioPharm Brief covers positive phase 3 melanoma results for Merck and Moderna’s individualized neoantigen therapy, a personalized cancer vaccine manufacturing platform entering clinical use, and a new brain-penetrant antibody approach for glioblastoma. Welcome to The …
Merck and Moderna announced that the vaccine-drug combo extended the time before cancer returned in high-risk patients, though specific duration metrics were not disclosed. Interim data from an earlier ASCO presentation indicated a halving of melanoma return risk after five years.
Moderna’s personalized cancer vaccine has scored a late-stage win, validating the commercial and clinical viability of neoantigen targeting. This success establishes a new standard for adjuvant treatment in high-risk melanoma patients.
Moderna’s personalized cancer vaccine has scored a late-stage win, confirming the efficacy of its mRNA platform in preventing melanoma recurrence. This milestone underscores the potential for neoantigen vaccines to become a cornerstone of oncology treatment.
Merck and Moderna’s success opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, the personalized vaccine trains the immune system to specifically target mutations found only on a person's tumor, with thousands of melanoma patients expected to benefit upon approval.
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial, the companies announced Wednesday, bringing them one step closer to filing for approval of the treatment option. The mRNA-based shot in combinati…
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push Fierce Biotech
Moderna and Merck announced positive Phase 3 results for their jointly developed personalized mRNA cancer vaccine in high-risk melanoma patients, marking a historic milestone for mRNA technology in oncology. Combining the vaccine with Keytruda significantly delayed cancer recurre…
According to the National Cancer Institute, in 2023 more than 1.5 million people in the US suffered from melanoma Merck and Moderna’s experimental personalized cancer vaccine has shown promising success in Melanoma’s first-ever late-stage trial. The landmark success in the trial …
A Phase III trial of intismeran autogene, the mRNA-based individualized neoantigen therapy co-developed by Merck (NYSE: MRK) and Moderna (Nasdaq: MRNA), has met both its primary and a key secondary endpoint in patients with completely resected stage IIB-IV melanoma, the companies…
Merck and Moderna’s experimental personalized cancer vaccine has delivered positive results in its first phase three trial, the companies announced Wednesday, moving the treatment closer to potential regulatory approval The mRNA vaccine, combined with Merck’s Keytruda, met the ma…
Moderna's personalized cancer vaccine shows success in Phase 3 trial The Business Journals
Moderna is headquartered at 325 Binney Street in Cambridge. Moderna Inc.’s personalized cancer vaccine is now one big step closer to seeking approval. Merck and Moderna said that new Phase 3 data showed intismeran autogene combined with Keytruda reduced melanoma recurrence and sp…
Moderna and Merck's jointly developed personalized mRNA cancer vaccine has succeeded in suppressing cancer recurrence and metastasis in high-risk melanoma patients in a late-stage clinical trial. This marks the first time a personalized mRNA cancer therapeutic has met its primary…
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed the combo significantly extended…
Merck and Moderna are advancing their individualized neoantigen therapy (INT) platform, leveraging mRNA to train immune systems against patient-specific tumor fingerprints. This commercial partnership highlights the industry's pivot toward 'one medicine for one patient' models, aiming to address genetic uniqueness in cancer care.
Merck and Moderna are advancing individualized neoantigen therapy (INT) to train patients' immune systems against tumor-specific neoantigens using mRNA. This partnership underscores the industry shift toward 'one medicine for one patient' strategies, leveraging the unique genetic fingerprint of each tumor to guide clinical development.
Follow-up data from the phase 2b KEYNOTE-942 trial shows that BioNTech’s mRNA-4157 combined with pembrolizumab reduced the risk of recurrence or death by 49% in high-risk stage III/IV melanoma patients compared to pembrolizumab alone. The combination also cut the risk of distant metastases or death by 62% at a median follow-up of three years. These results support the clinical benefit of personalized neoantigen mRNA vaccines in adjuvant settings.
A recent review in Signal Transduction and Targeted Therapy highlights the clinical translation of personalized mRNA vaccines, citing Moderna’s mRNA-4157 and BioNTech’s autogene cevumeran for reducing recurrence risk. The article contrasts these advances with the historical limitations of therapeutic cancer vaccines, noting Sipuleucel-T as the sole FDA-approved example to date. It outlines various vaccine platforms and the immunological challenges remaining in the field.